Roth Capital Assumes BioRestorative Therapies Inc. (BRTX) at Buy, PT $15

Roth Capital analyst Jonathan Aschoff assumes coverage on BioRestorative Therapies Inc. (NASDAQ: BRTX) with a Buy rating and a price target of $15.00.

The analyst comments "Following coverage transfer, we have established a Buy rating and $15 price target, which is supported by a DCF analysis using a 45% discount rate applied to all cash flows and the terminal value, which is based on a 5x multiple of our projected 2031 operating income of $429 million. We anticipate substantial ramping of BRTX-100 Phase 2 enrollment starting in 2Q23, after our expected favorable 1Q23 DSMB meeting and activation of all sites, and to ThermoStem progression toward IND."

For an analyst ratings summary and ratings history on BioRestorative Therapies Inc. click here. For more ratings news on BioRestorative Therapies Inc. click here.

Shares of BioRestorative Therapies Inc. closed at $3.25 yesterday.

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Adeia (ADEA) PT Raised to $50 at BWS Financial
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)